Lisata Therapeutics (NASDAQ:LSTA) Trading 0.8% Higher – Should You Buy?

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was up 0.8% during mid-day trading on Thursday . The stock traded as high as $2.68 and last traded at $2.64. Approximately 19,329 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 81,272 shares. The stock had previously closed at $2.62.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a research note on Wednesday, December 11th.

Lisata Therapeutics Stock Performance

The firm has a market cap of $22.15 million, a price-to-earnings ratio of -1.05 and a beta of 1.14. The stock’s fifty day moving average is $3.02 and its two-hundred day moving average is $2.99.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same quarter last year, the business posted ($0.65) earnings per share. Sell-side analysts predict that Lisata Therapeutics, Inc. will post -2.66 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP lifted its stake in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.